Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acclaim-2: Quaratusugene Ozeplasmid + Pembrolizumab in Previously Treated NSCLC
NCT05062980Phase 1Terminated
- Sponsor
- Genprex, Inc.
- Start
- Mar 2022
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of quaratusugene ozeplasmid in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Genprex, Inc. Primary endpoints: Recommended Phase 2 Dose at 21 days and Progression-Free Survival at 8 months. Started Mar 2022; status: terminated.
02
Drugs
quaratusugene ozeplasmid
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05062980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062980.